training meetings
training meetings with http://www.mdnewscast.net

training meetings

Medical Newscast

News for 29-Feb-24

Source: MedicineNet Diabetes General
Insulin Prices Skyrocket, Putting Many Diabetics in a Bind

Source: MedicineNet Diabetes General
Health Tip: Prepare for Travel With Diabetes

Source: MedicineNet Diabetes General
Standing or 'Easy' Walks May Help Type 2 Diabetics Control Blood Sugar

Source: MedicineNet High Blood Pressure General
Stressed Childhood Might Raise Risk for High Blood Pressure Later

Source: MedicineNet Diabetes General
Low Blood Sugar Linked to Death Risk for Hospital Patients

Source: MedicineNet Diabetes General
Chemo More Damaging to Hearts of Diabetics: Study

Source: MedicineNet Diabetes General
Jardiance (empagliflozin)

Source: MedicineNet Diabetes General
FDA OKs High-Tech Diabetes Device to Help Replace Fingerstick Tests

Source: MedicineNet High Blood Pressure General
High Blood Pressure Rates Have Doubled Worldwide Since 1975

Source: MedicineNet High Blood Pressure General
Bonus From Your Blood Pressure Med: Fewer Fractures?

Search the Web
training meetings
alcohol anonymous meetings
executive meetings
morning meetings
adult children of alcoholics meetings
face to face meetings
scheduling meetings
meetings aériens
rules of meetings
four meetings

The Best training meetings website

All the training meetings information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best training meetings site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
training meetings.

training meetings

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

If you are truly interested in the very best in training meetings then be sure you click the link above. We have researched the training meetings subject extensively and can guarantee that the people have the best.

The training meetings links on the left side of this page will take you directly to the specific item you need so look around. We have made it easy for you and of course this company stands behind their training meetings with total satisfaction guarantees.

training meetings

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

training meetings information exists in a large variety of formats and genres (facts, opinions, training meetings stories, interpretations and so on). This information has been created to inform, persuade and educate you on all that you ever need to know about training meetings. The quality ranges from poor to brilliant with lots of shades in between.

This website has been developed from painstaking research covering all areas of training meetings. We undertook this research initially for ourselves because we have a genuine interest in training meetings. We now wish to share this information with you so that you can directly benefit from our research. When you click on our links and follow our leads you can be confident that we have trod the road ahead and discovered the highest quality information.

Class of Drugs Brings Hope to Cancer Patients

 by: ARA Content

(ARA) - This is an exciting time in cancer research. Recent information on angiogenesis -- the growth of new blood vessels -- is providing researchers opportunities to find new ways to slow or stop a tumor's growth by cutting off the blood supply it needs.

Angiogenesis performs a critical role in the development of cancer. To grow, solid tumors need oxygen and nutrients provided by new blood vessels. Once a vascular network has been generated, cancer cells can also invade the rest of the body, a process called metastasis. Currently, researchers believe that more than 90 percent of all cancer cases are angiogenesis-dependent.

The good news is that a novel class of drugs, which acts as angiogenesis inhibitors, shows great potential in fighting more than 20 different diseases, including many types of cancer.

These "anti-angiogenesis" drugs being developed and tested block the formation of new blood vessels, starving cancerous cells and stopping tumor growth. One drug being tested, Neovastat, was discovered in 1994 and is derived from cartilage tissue. Neovastat is the only angiogenesis inhibitor being developed in the biotechnology and pharmaceutical universe that has four mechanisms of action to combat blood vessel growth. Furthermore, Neovastat is taken orally, making it convenient for patients who need long-term treatment, and it has shown minimal side effects in clinical trials. This means that unlike standard chemotherapy, Neovastat is not likely to interfere with a patient's immune system, or cause adverse gastrointestinal symptoms or hair loss.

In addition, because most cancer cells are genetically unstable and more prone to mutations, resistance is a major problem with many chemotherapy agents. But since anti-angiogenesis drugs target normal endothelial cells that are not genetically unstable, drug resistance is less likely to develop and has not been a problem so far in clinical trials.

Another hope is that angiogenesis inhibitors can be used in combination with therapies that directly target tumor cells. Because anti-angiogenic drugs and chemotherapy are aimed at different cellular targets, it is possible that the combination will prove even more effective than either therapy is as a stand-alone.

Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer for which there are urgent needs for new therapies. For multiple myeloma, the second most common form of blood cancer, the drug is in phase two trials with 125 patients in the United States, Canada and Europe. This trial should be completed by the end of 2002. For progressive renal cell carcinoma, the drug is in phase three trials with 280 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a phase three trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess test results and make decisions on approval.

Neovastat is being developed by Aeterna Laboratories of Quebec, Canada. For more information about current trials, call (888) 349-3232. If you are an oncologist, contact Claude Hariton, PhD, vice president of Clinical and Regulatory Affairs, (418) 652-8525, Ext. 306.

To learn more about anti-angiogenesis and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

About The Author

Courtesy ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

Google

http://www.medmeet.com/
Go Meetings | Fantasy Football Update | Medical Meetings | Medical Meetings | Doctors On-the-Net

Present On The Net   Affordable Used Cars   Medical Newscast